Benjamin Carr, Ph.D. 👨🏻💻🧬<p><a href="https://hachyderm.io/tags/Sana" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Sana</span></a>’s cell therapy may be ‘transformative cure’ for type 1 <a href="https://hachyderm.io/tags/diabetes" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>diabetes</span></a><br><a href="https://hachyderm.io/tags/Biotech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Biotech</span></a> is evaluating UP421, donor-derived allogeneic primary islet cell therapy, as <a href="https://hachyderm.io/tags/T1D" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>T1D</span></a> treatment that doesn’t require <a href="https://hachyderm.io/tags/immunosuppression" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>immunosuppression</span></a>. Four weeks after cells were transplanted into patient’s arm, therapy had avoided immune rejection and was tied to consistent levels of c-peptide expression—a biomarker that indicates if the transplanted beta cells are producing <a href="https://hachyderm.io/tags/insulin" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>insulin</span></a>.<br><a href="https://www.fiercebiotech.com/biotech/sanas-cell-therapy-may-be-transformative-cure-type-1-diabetes-analysts" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">fiercebiotech.com/biotech/sana</span><span class="invisible">s-cell-therapy-may-be-transformative-cure-type-1-diabetes-analysts</span></a><br><a href="https://archive.ph/dT0Vd" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="">archive.ph/dT0Vd</span><span class="invisible"></span></a></p>